BSEM (BioStem Technologies) Market Cap: $60.9 Mil (As of Jun. 26, 2026)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.59
GF Value $139.96
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Market Cap?

BioStem Technologies BSEM +4.22% 49 Market Cap is $60.9 Mil as of Jun. 26, 2026. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, BioStem Technologies ranks worse than 60.17% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioStem Technologies's share price for the quarter that ended in Sep. 2025 was $4.69. BioStem Technologies's Shares Outstanding (EOP) for the quarter that ended in Sep. 2025 was 16.8 Mil. Therefore, BioStem Technologies's market cap for the quarter that ended in Sep. 2025 was $78.6 Mil.

BioStem Technologies's quarterly market cap increased from Sep. 2024 ($162.2 Mil) to Dec. 2024 ($230.3 Mil) but then declined from Dec. 2024 ($230.3 Mil) to Sep. 2025 ($78.6 Mil).

BioStem Technologies's annual market cap increased from Dec. 2022 ($36.4 Mil) to Dec. 2023 ($95.0 Mil) and increased from Dec. 2023 ($95.0 Mil) to Dec. 2024 ($230.3 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioStem Technologies's Enterprise Value for Today is $37.1 Mil.


BioStem Technologies  (OTCPK:BSEM) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


BioStem Technologies Market Cap Related Terms


BioStem Technologies Market Cap Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Market Cap Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.40 12.15 36.36 95.01 230.34

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.50 95.01 162.21 230.34 78.63

BSEM vs TCRX, BYSI, MCRB: Market Cap Comparison

For the Biotechnology subindustry, BioStem Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Market Cap distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Market Cap falls into.


BSEM
49GF Score
BioStem Technologies Inc BSEM
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

BioStem Technologies's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=$13.84*16.643
=$230.3

BioStem Technologies's Market Cap for the quarter that ended in Sep. 2025 is calculated as

Market Cap (Q: Sep. 2025 )=Share Price (Q: Sep. 2025 )*Shares Outstanding (EOP) (Q: Sep. 2025 )
=$4.69*16.765
=$78.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $60.9 Mil mean?
BioStem Technologies (BSEM) has a Market Cap of $60.9 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #861 out of 1431 companies in the Biotechnology industry, placing it in the top 60.2%.
Is BioStem Technologies' Market Cap too high?
BioStem Technologies' current Market Cap is $60.9 Mil. The Biotechnology industry median Market Cap is 113.83. BioStem Technologies' value of $60.9 Mil is 46.5% below this industry median. Based on the distribution chart, BioStem Technologies ranks #861 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Market Cap compare to TCRX and BYSI?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #861 out of 1431 companies for Market Cap. This places BioStem Technologies in the lower half of its industry. The industry median Market Cap is 113.83. BioStem Technologies' value of $60.9 Mil is 46.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Market Cap of $60.9 Mil is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Market Cap is $60.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.59 — trading 97.4% below its estimated fair value. The current Market Cap is $60.9 Mil and 46.5% below the Biotechnology industry median of 113.83. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Market Cap is $60.9 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.59 is trading 97.4% below its estimated GF Value™ of $139.96. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • Market Cap: $60.9 Mil
  • GF Value™: $139.96 vs. price of $3.59 (97.4% below fair value)
  • GF Score™: 49/100 with 3 warning signs
  • Industry Position: 46.5% below the Biotechnology median (#861 of 1431)

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$139.96
GF Value